Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Pas encore traduit Pas encore traduit
Auteurs
Catégorie Primary study
Registry of Trialsclinicaltrials.gov
Year 2008

Cet article est inclus dans 1 Systematic review Systematic reviews (1 reference)

This article is part of the following publication threads:
Loading references information
The primary objective was to compare the efficacy of once daily subcutaneous injections of Semuloparin sodium (AVE5026) with placebo in the prevention of venous thromboembolism \[VTE\] in cancer patients at high risk for VTE and who were undergoing chemotherapy.

The secondary objectives were to evaluate the safety of Semuloparin sodium (AVE5026), to document Semuloparin sodium (AVE5026) exposures, to try identifying a metagene predictor of VTE and to assess the survival status at one year in this population.
Epistemonikos ID: 844e456063c1ee83bdd59082ab56a4faa8cd49de
First added on: Mar 14, 2016